Ionis Pharmaceuticals (IONS) PT Lowered to $45 at Piper Sandler
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Piper Sandler analyst Tyler Van Buren lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $45.00 (from $55.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BlueScope Steel Limited (BSL:AU) (BLSFY) PT Raised to AUD22.50 at Credit Suisse
- Movida Participacoes SA (MOVI3:BZ) PT Lowered to R$20 at Morgan Stanley
- Hana Financial Group (086790:KS) PT Raised to KRW51,000 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!